These trials have provided key pieces of information including the following: similar effectiveness of methotrexate and mycophenolate mofetil for intermediate, posterior, and pan- uveitis; usefulness of interferon-beta for intermediate uveitis; and potent anti-inflammatory activity of adalimumab in recalcitrant uveitis. This evidence concerns the gene IFNB1 and uveitis.